The Meeting of the Transparency Council No. 37/2022 of 19.09.2022
The agenda includes:
Preparing a position on the evaluation of the drug of Kerendia (finerenone) for the indication: treatment of patients with chronic kidney disease (stages 3 and 4, with albuminuria) associated with type 2 diabetes mellitus in adults treated with insulin.
Preparing opinions on draft health policy programmes of local government units:
- ,,Pre-health first aid education and health programme for schoolchildren for 2022-2024” (Municipality of Kwidzyn),
- ,,Health policy programme for prevention and early detection of colorectal cancer among the residents of the Podlaskie Voivodeship”.
Preparing opinions on the inclusion in the reimbursement procedure of drugs containing the active substances:
- spironolactone for the indication: post-infarction left ventricular systolic dysfunction,
- bisoprolol for the indication: supraventricular tachyarrhythmias – in patients over 6 years of age,
- amoxicillin for the indication: infections in immunocompromised patients – prophylaxis,
- amoxicillin + clavulanic acid for the indication: infections in immunocompromised patients – prophylaxis,
- sulfamethoxazole + trimethoprim for the indication: infections in patients treated with cyclophosphamide – prophylaxis,
- chlorambucil for the indication: amyloidosis,
- tacrolimus for the indications: idiopathic nephrotic syndrome – in case of cyclosporine intolerance or cyclosporine resistance; lupus nephritis – in case of cyclosporine intolerance or cyclosporine resistance.